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Special populationsAbstract Background: Breast cancer and HCV are two frequent diseases in Egypt. There is a
considerable probability of concurrent affection. This concurrence creates a subpopulation, which
needs special evaluation and care.
Objective: To evaluate a subset of Egyptian breast cancer patients receiving Doxorubicin based
adjuvant chemotherapy, with HCV seropositivity (group 2) compared to HCV seronegative patients
(group 1).
Methods: 102 breast cancer patients, planned to receive Doxorubicin based adjuvant chemother-
apy, at the Oncology Department, Alexandria Faculty of Medicine, were recruited since June
2009. Pretreatment evaluation included serological testing for HCV. FAC Adjuvant chemotherapy
was given for six cycles.
Results: HCV seropositivity was detected in 52 cases. Two cases in the seropositive group devel-
oped toxic hepatitis and discontinued treatment and follow up. The remaining 100 patients suffered
comparable toxicities, except for more frequent liver enzyme elevations in the seropositive group.
Diarrhea was also more frequent in the seropositive group. Treatment delays and dose reductions
were more frequently observed in the seropositive group. The 36 month disease-free survival and
relapse pattern were not signiﬁcantly different between the two groups.
288 K.Y. Welaya et al.Conclusion: Patients receiving chemotherapy should undergo screening for the virus. Most patients
with HCV were able to tolerate chemotherapy and continue the initial chemotherapy plan, without a
signiﬁcant change in the toxicity proﬁle or the natural course of their malignancy. Dose or regimen
adjustments may be of help to less tolerant patients. A preemptive 10% initial Doxorubicin dose
reduction might reduce the frequency of severe toxicity for selected patients. The assistance of a gas-
troenterologist in HCV positive breast cancer patients, planned for chemotherapy is important.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Breast cancer is a major medical problem with signiﬁcant pub-
lic health and societal ramiﬁcations. It is the most common
cancer in women.1 In the latest cancer statistics published by
the American Cancer Society in early 2014, the incidence of
breast cancer in the United States is over 230,000 cases each
year and it is responsible for over 40,000 deaths.2 Breast cancer
incidence rates are highest in more developed countries with
lower incidence in less developed countries.3,4
In a hospital-based Egyptian cancer statistics report of the
NCI (Cairo), breast cancer constituted 18.9% of total cancer
cases (35.1% in women and 2.2% in men) and was the most
common cancer among women in this series.5 The diagnosis
was made at a younger median age than in European and
North American countries, with a relatively advanced tumor
presentation.6 Such a disease proﬁle emphasizes the role of
systemic treatment in the multidisciplinary management of
breast cancer patients in Egypt.
The Early Breast Cancer Trialists’ Collaborative Group
overview of adjuvant chemotherapy trials has shown an
‘‘increase in survival beneﬁt over time from polychemotherapy
versus no adjuvant chemotherapy, twice as great at 15 years as
it was at ﬁve years (10 versus 4.7%)’’, in women under the age
of 50.7 Young and old women have shown similar propor-
tional reductions in recurrence and breast cancer-speciﬁc
mortality.8
Among the most widely used adjuvant chemotherapy regi-
mens, anthracycline-based therapy has become a standard,
unless the patient had a contraindication to anthracyclines.9,10
Toxicities from adjuvant chemotherapy must be weighed in the
balance between the survival gains versus quality of life impact
in premenopausal and postmenopausal patients.11a Institutional Review Board Information http://ohrp.cit.nih.gov/
search/IrbDtl.aspx1.1. Chemotherapy and liver disease
Chemotherapy can have a direct hepatotoxic effect or may
trigger a worsening of preexisting liver disease, especially viral
hepatitis. Conversely, a diseased liver will result in alteration of
the metabolism and excretion of chemotherapy drugs that rely
upon the liver for their clearance. This can result in increased
systemic toxicity or worsening of chemotherapy-induced hepa-
totoxicity.12 Cyclophosphamide is metabolized by the liver to
the cytotoxic metabolite. It is infrequently hepatotoxic.13,14
Increased toxicity has not been reported in patients with hepa-
tic dysfunction.15 Doxorubicin is extensively metabolized in
the liver; and 80% of each dose is excreted in the bile. Isolated
case reports have suggested that Doxorubicin can cause
hepatotoxicity.15 Patients with cholestasis have delayedclearance of Doxorubicin and its metabolites and develop
greater systemic toxicity from standard doses.16 5-Fluorouracil
is metabolized in tissues to its active form. Approximately 10%
of administered 5-FU is excreted unchanged in the urine, while
the remainder is enzymatically catabolized primarily in the
liver. Rare reports of hepatotoxicity have been noted with
intravenous 5-ﬂuorouracil.17
Liver injury is primarily assessed by liver function tests.
Radiological studies may be needed to differentiate drug
toxicity from biliary, vascular, or tumor-related conditions.18
Criteria have been developed to grade the severity of
treatment-related abnormalities in liver function tests and
adjust the dose in patients undergoing chemotherapy.15
1.2. Hepatitis C virus
HCV infection has become an increasingly serious health prob-
lem in different parts of the world.19 Egypt has possibly one of
the highest HCV prevalence rates in the world. HCV is the
leading cause of HCC and chronic liver disease in the coun-
try.20 It is reported that more than 50% of infected people
are unaware of their disease, leading to the spread of infection
and lost treatment opportunities.21
Modern serological HCV diagnostic tests have good sensi-
tivity and speciﬁcity particularly in high risk patient groups
and their use for screening in these populations has been rec-
ommended.22 Given the prevalence rates of HCV and breast
cancer in Egyptians, a signiﬁcant chance of a concurrent affec-
tion is present and warrants screening in breast cancer cases
planned for treatment.
This study was conducted to evaluate the experience of
Egyptian breast cancer patients receiving Doxorubicin based
adjuvant chemotherapy, in association with HCV seropositiv-
ity compared to HCV seronegative patients.
2. Patients and methods
This observational cohort study was conducted after the
approval of the IRB of Alexandria Faculty of Medicine in
April 2009 (IRB No: 00007555-FWA No: 00018699).a It
included a total of 102 pathologically proven breast cancer
patients, recruited since June 2009, who were planned to
receive Doxorubicin based adjuvant chemotherapy, at the
Oncology Department, Alexandria Faculty of Medicine,
Alexandria University. They were chosen according to the
following criteria:
Table 1 Patient characteristics.
Total number 102
Male:female 1:101
Age (years) 29–69 (Median = 48.5)
Comorbidities
Diabetes Mellitus 27 (27.54%)
Hypertension 23 (23.46%)
Other 18 (18.36%)
Pretreatment LVEF (%) 55–74 (Median = 63.5)
Stage
Stage I 11 (11.22%)
Stage II 67 (68.34%)
Stage III 24 (24.48%)
Pathology
IDC 94 (95.88%)
ILC or mixed 8 (8.16%)
Grade
Well diﬀerentiated 8 (8.16%)
Moderately diﬀerentiated 52 (53.04%)
Poorly diﬀerentiated 33 (33.66%)
Hormone receptor positivity 82 (83.64%)
HCV seropositivity 52 (53.04%)
Average body surface area 1.845 m2
LVEF: left ventricular ejection fraction.
IDC: inﬁltrating ductal carcinoma.
ILC: inﬁltrative lobular carcinoma.
HCV: hepatitis C virus.
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0–2.23
2. Adequate bone marrow function (white blood cell
count > 3000/dl,
3. platelet count > 100,000/dl and hemoglobin > 9gm /dl)
4. Adequate liver and renal functions (61.5 times the upper
limit of normal)
5. Age 20–70 years at the time of inclusion
6. A signed consent obtained from each patient before
inclusion in this study, as required by the IRB.
7. LVEF more than 50% measured by echocardiography.
Patients were excluded, if they had one or more of the
following conditions:
1. Pregnancy and lactation.
2. Any cardiac disease, or a serious medical or psychiatric
condition.
3. Previous liver disease or primary or secondary hepatic
malignancy.
4. Refusal of treatment.
All patients included in this study were subjected to pre-
treatment clinical, radiological and laboratory evaluation,
including peripheral blood count, kidney and liver function
tests. HCV antibody testing using Enzyme Linked Immuno-
sorbent Assay (ELISA) was performed on all the patients
and accordingly they were classiﬁed into 2 groups, the ﬁrst
group included 50 HCV negative patients (group 1) and
another group including 52 HCV positive patients (group 2).
All patients were intermediate and high risk breast cancer
and were planned to receive anthracycline chemotherapy in
the adjuvant setting which started from 4–6 weeks after
surgery. The surface area was calculated in both groups by
the formula of Mosteller using both the weight and height of
each patient to calculate the dose of chemotherapy given to
each patient.24 All patients received CAF regimen (cyclophos-
phamide 500 mg/m2, adriamycin 50 mg/m2 and 5-ﬂurouracil
500 mg/m2) given intravenously on day 1 of each cycle. The
cycles were repeated every 21 days for a total of 6 cycles. All
patients received antiemetic premedication with Ondansteron,
Ranitidine and Dexamethasone by intravenous route, 15 min
before starting the chemotherapy.
On day 1 of each cycle, each patient was assessed clinically
and by laboratory investigations including peripheral blood
count, serum kidney and liver function tests. Toxicities were
recorded according to the Common Terminology Criteria
Adverse Event version 4.23 Dose modiﬁcations and/or treat-
ment delay if needed were done according to the laboratory
ﬁndings, with the guidelines for each individual drug.25 Ejec-
tion fraction was measured after ﬁnishing the six cycles. An
estimate of the average dose given to each group was calcu-
lated, with compensation for the average delay per patient,
considering a relative effective dose reduction of 25% of a
cycle dose for a 1 week delay of that cycle.26
Statistical analysis was performed using SPSS/Win version
16. Chi square and Fisher’s Exact test (if Chi Square test is not
applicable in 2 · 2 tables) were done for non-parametric eval-
uation of data. Odds ratio and 90% conﬁdence interval were
calculated for comparing odds of toxicity and delay endpoints.
Multiple linear regression was done on factors affecting liver
enzyme levels in each cycle. Analysis included HCV status,age, diabetic status, hypertension and menstrual status. For
each cycle there was a model which was analyzed for signiﬁ-
cance. Kaplan Meier disease-free survival curves were plotted.
3. Results
One hundred and two patients were included in the study.
Fifty of them were HCV seronegative (group one) and
ﬁfty-two were HCV seropositive (group two). Patient charac-
teristics were comparable in both groups with no statistically
signiﬁcant difference (Table 1).
3.1. Chemotherapy induced toxicity
3.1.1. Laboratory toxicity
There was no statistically signiﬁcant difference between both
groups regarding the frequency and grade of anemia, neutro-
penia or thrombocytopenia throughout the course of treat-
ment. All patients experienced anemia but none reached
grade 3 throughout the course. Grades 3–4 neutropenia were
observed after the ﬁfth cycle in 10% (ﬁve patients) and 4%
(two patients) of group one and two respectively. Grade 1
thrombocytopenia was observed in four patients, two in each
group, and was reversible.
Most patients did not suffer any renal impairment. One
patient in group two had elevated serum creatinine and blood
urea. It reached grade 2 after the ﬁrst, fourth and ﬁfth cycles
but it was still controlled with increased ﬂuid intake. Four
other patients had transient elevated blood urea and creati-
nine, one of them in group one and none of them exceeded
grade 1.
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Figure 1 Mean SGOT level throughout the course of treatment.
OR 4.125 (90% CI: 1.8742–9.0788).
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Figure 2 Mean SGPT level throughout the course of treatment.
OR 3.777 (90% CI: 1.8846–7.5728).
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Figure 3 The incidence of diarrhea throughout the course of
treatment. OR 14.636 (90% CI: 5.5084–38.8902).
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elevation, with manifestations of severe toxic hepatitis. The
liver proﬁle for these two patients was not corrected by liver
support and they discontinued their chemotherapy. Differ-
ences between the two groups in the grade and frequency of
liver enzyme elevations started to be signiﬁcant after the third
cycle of chemotherapy (Figs. 1 and 2). Throughout the whole
six cycles of chemotherapy, 42% (twenty-one patients) of
group two patients developed elevated SGOT compared to
28% in group one (OR= 4.125, 90% CI: 1.8742–9.0788), all
of these patients were grade 1 and 2. As regards SGPT level,
34% of patients in group two had elevated SGPT level com-
pared to 18% in group one (OR 3.777 with 90% CI from
1.8846 to 7.5728). None of the study population, who contin-
ued for the 6 cycles, experienced any levels of elevated bilirubin
except for one patient in group two who had grade 1 transient
elevation after the sixth cycle.
3.1.2. Clinical toxicity
Nausea was the most common side effect in the whole studied
population. It was more frequent in group one patients. The
incidence of high grade nausea was similar in both groups,
except after the fourth cycle, where 28% (fourteen patients)
and 6% (three patients) had grade 3 nausea in group one
and two respectively (p 6 0.001).
Vomiting was the second common side effect among the
studied population. The incidence of high grade vomiting
was statistically similar in both groups as 44% of the patients
in group one had grade 3–4 compared to 40% in group two
throughout the whole cycles.
Diarrhea was the clinical toxicity showing the most signiﬁ-
cant difference between both groups regarding the clinical tox-
icity proﬁle (Fig. 3). Overall, 28% of the patients in group two
experienced grade 3–4 compared to 4% only in group one
through the six cycles of chemotherapy. (OR = 14.636, 90%
CI 5.5084–38.8902).
Grade 3 stomatitis was more common in group one patients
(20% versus 16%). The incidence of stomatitis was higher in
group one after cycle V where 62% (thirty-two patients) had
stomatitis compared to 44% (twenty-two patients) in group
two. This was also observed after the sixth cycle where theincidence of stomatitis was 62% and 48% in group one and
two respectively (OR = 5.9341, 90% CI: 2.6278–13.4005).
Mild Skin changes, including skin discoloration and nail
changes, not exceeding grade 2, were more frequent in group
one and increased steadily throughout the course of treatment.
By the end of the sixth cycle, 100% and 98% of patients of
group one and group two respectively had grade 2 alopecia.
After six cycles, cardiac toxicity in terms of grade 1 change
in ejection fraction was observed in 70% and 58% of group
one and group two respectively, but the difference was not
statistically signiﬁcant (p= 0.211).
3.2. Dose delay and modiﬁcation
In group one, the range of the overall treatment duration was
15–19 weeks, while in group two the range of the overall treat-
ment duration was a bit wider ranging from 15 to 21 weeks
(Fig. 4). The majority of patients in both groups ﬁnished their
treatment on time. The number of patients with delays was
higher in group two (52%) than in group one (36%), excluding
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Figure 4 Overall treatment duration in groups 1 and 2.
OR = 0.5192 (90% CI = 0.2651–1.0168).
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Figure 5 Treatment delay > 17 weeks and dose modiﬁcation
OR for no delay and no dose modiﬁcation = 2.125 (90%
CI = 1.0744–4.2031). OR for delay > 17 weeks, in spite of dose
modiﬁcation (in HCV negative patients) = 0.3459 (90%
CI = 0.15–0.7977).
igure 6 Mean drug level as a percentage of the calculated dose.
Table 2 Relative dose and relative dose intensity in HCV
positive patients versus HCV negative patients.
Drug Relative dose (%) Relative DI (%)
Doxorubicin 87 90
Cyclophosphamide 97 92
5-Fluorouracil 96 93
Combined 92
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after the ﬁrst cycle and discontinued chemotherapy. HCV sero-
negativity was associated with a lower risk of treatment delays,
but the difference is not signiﬁcant (OR = 0.5192, 90%
CI = 0.2651–1.0168).
Fig. 5 demonstrates that 50% of the patients in group one
ﬁnished their course without delays or dose modiﬁcation com-
pared to 32% in group two, with OR= 2.125 (90%
CI = 1.0744 to 4.2031). Dose delays without dose modiﬁca-
tion or dose modiﬁcation without delay were comparable in
both groups (22% vs. 20% and 14% versus 16%). Patients
in group one had lower odds for dose delays >17 weeks in
spite of dose modiﬁcation in 14% compared to 32% in group
two, with OR = 0.3459 (90% CI = 0.15–0.7977).
Fig. 6 shows the mean percentage of the dose given for each
drug throughout the six cycles in both groups. The difference
between both groups is best demonstrated in the Doxorubicin
dose graph, which is considered to be the most hepatotoxic ofFthe three components of the protocol. The dose given for all
the studied population is gradually reduced in each consecutive
cycle until reaching the ﬁfth cycle where the difference between
both groups is best demonstrated. The estimate of the average
dose given to each group calculated, with compensation for the
average delay per patient, is reported in Table 2. The maxi-
mum delay and dose reduction affected the Doxorubicin rela-
tive dose. The other 2 drugs were less affected. The average
relative DI of FAC in HCV seropositive patients compared
to seronegative patients is 92%. Multiple linear regression
models were not signiﬁcant in the ﬁrst two cycles. After the
third cycle and onward, the model was signiﬁcant for the level
Figure 7 Kaplan–Meier 3-year disease-free survival. HCV sero-
negative ( ), n= 46; HCV seropositive ( ), n= 39.
Log Rank test: 0.260, p= 0.61.
Table 3 Pattern of failure.
HCV p
No (n= 44) Yes (n= 35)
No. % No. %
Local
No 38 86.36 27 77.14 0.286
Yes 6 13.64 8 22.86
Liver
No 34 77.27 24 68.57 0.385
Yes 10 22.73 11 31.43
Lung
No 34 77.27 28 80.00 0.770
Yes 10 22.73 7 20.00
Bone
No 39 88.64 29 82.86 FEp= 0.524
Yes 5 11.36 6 17.14
Total relapse
No 22 50.0 15 57.14 0.527
Yes 22 50.0 20 57.14
292 K.Y. Welaya et al.of SGOT and SGPT, where p was <0.01. HCV status was the
signiﬁcant predictor, for SGOT and SGPT increased levels,
except for SGPT in cycle 6. Age had an inverse impact on
SGOT for cycles 4, 5, and 6. The inverse effect of age on SGPT
was apparent in cycles 4 and 6 only.
3.3. Disease-free survival and patterns of recurrence
Of the 100 patients who were able to continue the 6 cycles of
chemotherapy, 6 patients in the HCV seronegative group
and 15 patients in the HCV positive group were untraced
and lost follow up. Kaplan–Meier disease free survival curves
(Fig. 7) were plotted for the remaining patients and showed no
signiﬁcant difference between both groups (Log Rank test:
0.26, p= 0.61), but the pattern of relapse was similar in both
groups (Table 3), with no statistically signiﬁcant difference.4. Discussion
Receiving chemotherapy is a very distressing and concern-
provoking stage of the treatment of breast cancer, associated
with decrease in overall quality of life.27,28 Endemic HCV
infection can be exacerbated with cytotoxic agents.29 HCV
positive patients receiving chemotherapy are already burdened
with associated comorbidities and may be less tolerant to
adverse events of the chemotherapy.30
Fallahian et al. reviewed the literature for viral hepatitis
reactivation in immune suppressed patients and patients under
chemotherapy. The reviewed studies showed a ‘‘less clear
relationship between chemotherapy and HCV reactivation
than HBV’’. Mild abnormalities of liver enzymes were
reported. HCV appeared to increase the risk of veno-occlusive
disease in transplant patients. The authors advocated the use
of HCV antiviral treatment for progressive cases of
reactivation.31
Torres and Davila in their review on hepatitis virus reacti-
vation in cancer patients stated that: ‘‘HCV reactivation seems
to be less common than HBV reactivation and is usually asso-
ciated with a good outcome and low mortality. However, once
severe hepatitis develops, as a result of viral reactivation, mor-
tality rates seem to be similar among patients infected with
HBV or HCV. Liver damage owing to viral reactivation fre-
quently leads to modiﬁcations or interruptions of chemother-
apy, which can negatively affect patients’ clinical outcome’’.32
In the current prospective cohort study, the difference in
the toxicity proﬁle between HCV seropositive and seronegative
patients was mainly observed in the form of more frequent
reversible transaminase level elevations and more frequent
high grade diarrhea. Two cases developed severe hepatitis
precluding any further chemotherapy and were excluded from
further analysis. There were more delays in the HCV positive
group compared to the HCV negative group (52% versus
36%). High grade neutropenia was more frequent in group
2. There was no clear explanation regarding the high incidence
of diarrhea in the HCV positive patients compared to other
adverse effects. One reason could be attributed to the ﬁndings
of Fouad et al. which showed that Irritable bowel syndrome
was more frequent in HCV positive patients compared to
HBV patients and the normal controls.33
Morrow et al. reported an expansion of their retrospective
series analyzing the effects of chronic hepatitis C infection on
the treatment of 45 HCV positive breast cancer patients trea-
ted in MD Anderson Cancer Center (MDACC). Only 36
patients of the 44 received chemotherapy. Patients received dif-
ferent kinds of regimens including anthracyclines, taxanes, and
anthracycline plus taxanes, with or without trastuzumab. This
cohort was compared to a HCV negative historical control. Of
the 36 patients who received chemotherapy, 33 patients were
able to complete the initial planned number of cycles and nine
patients experienced elevations in the liver enzymes, graded as
1 or 2 toxicity. Twenty percent of their cases had prior antiviral
treatment and 39% received colony stimulating factor support
during treatment.34
The toxicity proﬁle in the current series and the ensuing
dose reduction/dose delays did not adversely affect the pattern
of relapse or disease-free survival. However, this observation
should be taken cautiously for two main reasons, ﬁrstly is
the short term follow up of the patients (36 months), longer
HCV serological status on Doxorubicin induced toxicity 293follow up is needed to accurately monitor the effect of dose
delay and modiﬁcation especially in the seropositive group,
secondly, the number of untraced cases and their unequal dis-
tribution between the two groups may distort the results.
4.1. Conclusion
HCV is an endemic infection in Egypt and all patients receiv-
ing chemotherapy should undergo screening for the virus.
Most patients with HCV were able to tolerate chemotherapy
well and continue the initial chemotherapy plan, without sig-
niﬁcant change in the toxicity proﬁle or the natural course of
their malignancy. Close monitoring of the patients would help
diagnose and promptly manage those with less tolerance to
treatment. Dose or regimen adjustments may be of help to
such patients. A preemptive 10% initial Doxorubicin dose
reduction might reduce the frequency of severe toxicity and
the consequent dose reductions and delays. It is important to
seek the assistance of a hepatologist/gastroenterologist in eval-
uating any HCV positive breast cancer patient who is planned
to receive chemotherapy.
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